Using high heated humidity to help with mucositis in stem cell transplant patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of high heated humidity (H3) delivered via the Airvo 2 device on patients undergoing autologous stem cell transplant for hematologic cancers. It is a phase II, open-label, case-control randomized trial comparing H3 to standard care in managing mucositis and related complications. The treatment is administered for a minimum of 4 hours per day during hospitalization, potentially extending up to 30 days for those with prolonged mucositis. The goal is to reduce the severity of complications and shorten hospital stays for patients receiving high-dose chemotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Minimum 18 years of age
2. Have given written consent prior to any study-specific procedures or have had an acceptable individual capable of giving consent on the patient's behalf.
3. Have one of non-Hodgkin lymphoma, Hodgkin lymphoma, or multiple myeloma and found to require high-dose, melphalan-based chemotherapy and autologous stem cell transplant (ASCT) as part of standard of care treatment (includes patients receiving ASCT also requiring oxygen).
4. Performance status of ECOG 0-2
5. Are reliable and willing to make themselves available for the duration of the study, and are willing to follow study procedures.

Exclusion Criteria:

1. Nasal blockage such as nasal polyps, deviated septum or nasal packing would either not allow the proper flow of heated humidity into the nares or it would be too uncomfortable to tolerate during the intervention.
2. Those with influenza like illness. The intervention is not in itself, an aerosol generating medical device. However, if influenza positive, there could be airborne spread of the virus impacting both staff and other patients.
3. Tracheostomy Tube Patients would require a different type of equipment attachment which is not included in this study. Tracheostomy tubes by-pass the upper airway and therefore the intervention cannot be used for the purpose of assessing mucositis. This intervention is used regularly on tracheostomy patients with good success however in this case, the upper airway is by-passed and therefore there would be no impact on mucositis.
4. Patients with significant co-morbidities that would prevent compliance of equipment use as determined by the treating physician.
5. Patients who have Obstructive Sleep Apnea who use a CPAP machine at night. This population would not be able to use the intervention concurrently with the CPAP device as both utilize the nares.

Where it's running

• Cross Cancer Institute
  Edmonton, Alberta, Canada Recruiting

Study contacts

• Principal investigator: Lisa Lem — Cross Cancer Institute, Alberta Health Services
• Study coordinator: Lisa Lem
• Email: Lisa.Lem@albertahealthservices.ca
• Phone: 780-432-8580

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combination of Pembrolizumab and BEAM for treating relapsed Hodgkin Lymphoma

  This study is testing if giving Pembrolizumab before and after a stem cell transplant can help people with relapsed Hodgkin Lymphoma feel better and have better outcomes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT06377540

• ATLG Levels During Autologous Stem Cell Transplant for MS

  This observational study will test ATLG pharmacokinetics and immune recovery in adults with multiple sclerosis undergoing autologous HSCT.

  Recruiting IRCCS San Raffaele · Milan, Italy · NCT07635693

• Providing food assistance to patients undergoing cancer treatment

  This study is testing whether giving food bags to cancer patients who struggle with food insecurity can help improve their nutrition and treatment outcomes.

  Recruiting University of Kansas Medical Center · Stanford, California and 3 other locations · NCT06802406

• Comparing two doses of olanzapine for preventing nausea in multiple myeloma patients receiving chemotherapy

  This study is testing whether two lower doses of olanzapine can help prevent nausea and vomiting in multiple myeloma patients receiving chemotherapy before a stem cell transplant.

  Recruiting Phase 3 Augusta University · Augusta, Georgia · NCT06588413

• Research sample repository for blood and cellular therapies

  This study is collecting blood samples to help researchers learn more about how to improve outcomes for people receiving blood and cell therapies.

  Recruiting Center for International Blood and Marrow Transplant Research · New Brighton, Minnesota · NCT04920474

• Comprehensive database for studying stem cell transplants and cellular therapies

  This study is creating a database to gather information on stem cell transplants and treatments to help improve recovery for patients and donors and make these therapies more accessible to everyone.

  Recruiting at 2 sites Center for International Blood and Marrow Transplant Research · Minneapolis, Minnesota and 1 other locations · NCT01166009

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.